First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North SydneyRecruitment to open this ...

However, there was ... Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer, Offers Potential for Targeted Therapy Jan. 13, 2024 — A newly developed PET imaging agent has been ...

Exelixis EXEL underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

Targeted therapy for thyroid cancer with BRAF and RET inhibitors has progressed to Phase II clinical trials with first results on the therapeutic response pending. Schematic representation of ...

More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary analysis of a target trial emulation of a comparative effectiveness study found.

Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.